Background: To report the results of repeated electrophysiological and visual field examinations in patients with vigabatrin-associated visual field loss (VGB-VFL) and the relationship between these electrophysiological findings, the cumulative dose of vigabatrin and the extent of visual field loss. Methods: Twenty-two eyes of 11 patients with VGB-VFL were studied. All patients underwent surgery for therapy-resistant epilepsy. Repeated electrooculograms (EOGs) and flash electroretinograms (ERGs) were made and the cumulative dose of vigabatrin and the visual field loss were recorded after a period of 37 - 47 months. Results: The visual field loss was stable in patients who had stopped vigabatrin at the time of the first examination. There wa...
Purpose: To investigate the clinical value of assessment of peripapillary retinal nerve fibre layer ...
Article abstract—Objective: To assess early visual impairment related to vigabatrin prospectively in...
Vigabatrin (VGB) is an antiepileptic drug approved for pediatric patients with infantile spasms. VGB...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Purpose: To determine the value of electrophysiological findings in patients with temporal lobe epil...
This thesis considers the visual electrophysiological effects of vigabatrin (an anti-epileptic drug,...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
Purpose In numerous studies vigabatrin medication has been associated with visual field constriction...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
Aim-To study the long term changes in the concentric contraction of the visual field in patients wit...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory e...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractor...
Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndr...
Purpose: To investigate the clinical value of assessment of peripapillary retinal nerve fibre layer ...
Article abstract—Objective: To assess early visual impairment related to vigabatrin prospectively in...
Vigabatrin (VGB) is an antiepileptic drug approved for pediatric patients with infantile spasms. VGB...
Background: To report the results of repeated electrophysiological and visual field examinations in ...
Purpose: To determine the value of electrophysiological findings in patients with temporal lobe epil...
This thesis considers the visual electrophysiological effects of vigabatrin (an anti-epileptic drug,...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
SummaryPurposeVigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people...
Purpose: To describe the correlation between visual field loss and the duration, dosage. and total a...
Purpose In numerous studies vigabatrin medication has been associated with visual field constriction...
Background: Use of the antiepileptic drug vigabatrin is associated with an elevated risk of visual f...
Aim-To study the long term changes in the concentric contraction of the visual field in patients wit...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractory e...
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add-on therapy in refractor...
Vigabatrin (VGB) has been widely used in patients affected by drug-resistant epilepsy and West syndr...
Purpose: To investigate the clinical value of assessment of peripapillary retinal nerve fibre layer ...
Article abstract—Objective: To assess early visual impairment related to vigabatrin prospectively in...
Vigabatrin (VGB) is an antiepileptic drug approved for pediatric patients with infantile spasms. VGB...